Sanofi names Novartis leader CEO; Novartis appoints president
Sanofi has named Paul Hudson as CEO, to succeed Olivier Brandicourt who is retiring. Hudson has been CEO of Novartis and a member of the Novartis executive committee.
“The board of directors would like to thank Olivier Brandicourt for the energy with which he has steered the group through a complex period and for his decisive contribution to the company’s return to growth. Thanks to the actions undertaken during his term of office, Sanofi is able to accelerate its growth, and has powerful assets to regain the position it needs to occupy,” Sanofi said.
The appointment is effective Sept. 1.
“Paul Hudson, 51 years old, is a seasoned leader with a strong international experience, particularly in the United States, Japan and Europe. He spent his 28-year career with major pharmaceutical companies such as Schering Plough, Astra Zeneca and Novartis, the company said, adding, “Throughout his various management positions, he has proven his strategic vision, his strong leadership and his ability to achieve the greatest challenges, particularly in terms of innovation and digital transformation. Mr. Hudson has a very robust track record in successful major product launches. Paul Hudson will move to Paris,” the company said.
In a separate development, Novartis announced that Marie-France Tschudin, currently president, Advanced Accelerator Applications, a Novartis company, has been appointed president, Novartis Pharmaceuticals. She will report to Vas Narasimhan, CEO Novartis, and will join the executive committee.
“I am pleased that Marie-France Tschudin is ready to take over from Paul Hudson to further grow the business and lead the expected upcoming launches of our transformative medicines. Marie-France has a strong record of accomplishments in driving commercial excellence and a culture of inclusiveness and integrity founded on her exemplary commitment to patients and customers. She has always been highly respected by people working with her and will bring new and diverse perspectives to our executive leadership team. I would like to thank Paul for his exceptional leadership in positioning our pharmaceuticals business for strong future growth. He also established a new culture of commercial excellence, integrity and nurtured a strong, diverse talent pool,” Novartis CEO Vas Narasimhan, said.
Tschudin has more than 25 years of broad, multi-national experience in the pharmaceuticals and biotech industry. She joined Novartis in January 2017. Before joining Novartis, she spent 10 years at Celgene in a variety of leadership and general management positions and led their Hematology-Oncology business for Europe, Middle East and Africa from 2014 to 2016.
No comments found